About Us
imc² in the news.
imc² Strengthens Pharmaceutical Expertise With New Senior Executives
Contact:
imc²
Angie Byrnes
214.224.1017
NEW YORK, March 29, 2005 – imc², a top interactive agency, announced today a number of new additions to help meet the explosive demand from pharmaceutical marketers for its high-impact interactive campaigns and services. The new hires, Andrew Chamlin, Daniel Goldberg, M.D., Amy West and John McMahan, come from both the client and agency sides and bring additional experience to imc²'s unmatched blend of interactive and pharmaceutical expertise.
Andrew Chamlin, a former director of marketing at Pfizer Inc., will serve as a vice president of imc²'s pharmaceutical practice and New York-based client services team. Joining imc²'s other senior practice leaders Hensley Evans and James Pietz, Chamlin will provide strategic direction and insight as well as oversee the successful delivery of client work. Mr. Chamlin, whose responsibilities will also involve leveraging client-side product management expertise to develop innovative, integrated marketing campaigns and concepts, led the campaign for Zyrtec-one of Pfizer's largest consumer marketing campaigns-that helped grow revenues from $765 million to $1.4 billion in less than four years. Prior to Pfizer, Chamlin also served as product director for Johnson & Johnson's Consumer Division, both in the United States and internationally. He also has deep experience in the advertising agency world, having held positions at both Young & Rubicam and Grey Advertising.
imc²'s new account director is Daniel Goldberg, M.D., who will apply his medical expertise to provide appropriate strategic direction in how to best communicate with physicians and consumers. Most recently, Dr. Goldberg was medical account director at BESTMED, a division of the Publicis Medical Education Group, where he spearheaded medical education management and strategic planning for AMBIEN and the launch of AMBIEN CR.
Amy West joins imc² as senior account manager after serving as the director of the Shire Pharmaceuticals account at Roska Direct. In that capacity, Ms. West drove the patient-centric direct response Internet marketing strategy for Shire's ADHD drug, Adderall XR, including e-relationship marketing that successfully supported the brand's diagnosis and treatment efforts.
John McMahan comes to imc² as an account manager in the pharmaceutical practice after four years at Eli Lilly and Company where he held various positions in e-marketing, DTC marketing and sales. Highlights of his work at Lilly include creating and implementing a disease-state online campaign that drove over 40,000 targeted physicians to Lilly's Web site.
"When you add these people to our current–and very talented–team, there's no question we are a premier interactive agency for pharmaceutical companies," commented Doug Levy, president and founder of imc². "These new team members are professionals who understand the complexities of pharmaceutical marketing and how to leverage the unique benefits that digital marketing can add to a campaign. We more than doubled our volume of pharmaceutical business in 2004, adding 12 new clients and 21 new brands, and this team will be critical to our growth and success as the demand from the pharmaceutical sector continues."
According to Levy, imc²'s pharmaceutical practice grew 120 percent from 2003 to 2004 and currently represents a roster of major clients such as GlaxoSmithKline, Johnson & Johnson, Novartis and Pfizer.
"One of the reasons for our success is that we do things a bit differently," he said. "A great example is imc² being one of the first interactive agencies to have an M.D. on staff. Not only will this help us better serve our pharmaceutical clients but it provides us with a tremendous internal capability and resource. Additionally, we're unique in that we begin each assignment by focusing on each client's business objectives. Only then do we start to think about how we can most effectively leverage digital marketing to meet those objectives through strategy, creative and technology."
